| Literature DB >> 35791026 |
Corina Schuster-Amft1,2,3, Jan Kool4, J Carsten Möller5,6, Raoul Schweinfurther5, Markus J Ernst7, Leah Reicherzer7, Carina Ziller1, Martin E Schwab8, Simon Wieser9, Markus Wirz10.
Abstract
BACKGROUND: There is a need to provide highly repetitive and intensive therapy programs for patients after stroke to improve sensorimotor impairment. The employment of technology-assisted training may facilitate access to individualized rehabilitation of high intensity. The purpose of this study was to evaluate the safety and acceptance of a high-intensity technology-assisted training for patients after stroke in the subacute or chronic phase and to establish its feasibility for a subsequent randomized controlled trial.Entities:
Keywords: High intensity; Physical exertion (MeSH); Stroke rehabilitation (MeSH); Technology-assisted training
Year: 2022 PMID: 35791026 PMCID: PMC9254509 DOI: 10.1186/s40814-022-01086-0
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
TIDieR checklist for intervention description
| Brief name | Highly intensive technology-assisted training (TAT) involving new technologies |
| Why | Technological devices were chosen with the prerequisite to provide feedback and allow a targeted, intensive, and dense training. |
| What (materials/procedures) | A broad range of available technological systems were used in the intervention, including VR-based, electromechanically assisted and sensor-based devices for gait, upper, and lower extremity training. The selection of therapy devices depended on the impairments of the patient and resources of the clinic. The following devices were used (in alphabetical order): Allegro Medical Device (Dynamic Devices, Zürich, Switzerland), Amadeo (tyromotion, Graz, Austria), Andago (Hocoma AG, Volketswil, Switzerland), Armeo Boom, Armeo Power and Armeo Spring (Hocoma AG, Volketswil, Switzerland), Bi-Manu-Trainer (Reha-Stim Medtec AG, Schlieren, Switzerland), C-Mill (c-mill-technologie AG, Port, Switzerland), EksoGT (EkSo Bionics, Richmond, USA), Erigo (Hocoma AG, Volketswil, Switzerland), FLOAT (Reha-Stim Medtec AG, Schlieren, Switzerland), Gloreha (Idrogenet srl, Lumezzane, Italy), HAL (Cyberdyne Inc, Tsukuba, Japan), Lokomat (Hocoma AG, Volketswil, Switzerland), mindmaze (MindMaze, Lausanne, Switzerland), MOTOmed (Reck, Betzenweiler, Germany), Myro (tyromotion, Graz, Austria), NuStep (NuStep LLC, Ann Arbor, USA), and Valedo Motion (Hocoma AG, Volketswil, Switzerland) |
| Who provided | The training was supervised or guided by an officially recognized physiotherapist, occupational therapist, or sports scientist/therapist holding a BSc or MSc degree. All therapists were specially trained in the use of the devices and experienced in treating neurological patients. |
| How | The ratio of patient to therapist was between 1:1 and 3:1. Safety for patients was ensured at all time. |
| Where | The training took place in one of the four participating rehabilitation centers. |
| When and how much | A training series lasted 4 weeks and comprised 3 to 5 training days per week. One training day included at least five trainings with a duration of 45 min per training. |
| Tailoring | Patients’ goals and preferences were incorporated. Patients received a tailored training plan based on the patient’s needs, impairments, and preferences. Absolute and relative contraindications for the training with any of the respective devices were considered. Training sessions were intensified by increasing exercise duration, resistance or complexity of the exercise. |
| Modifications | A maximum training break of 7 days was tolerated. If the maximal program (5 sessions/day) could not be tolerated by patients or due to scheduling reasons, a reduction of training intensity in terms of days, sessions/day, and/or duration of a session was considered. |
Comparison of required staff and time between therapeutic trainings without (reference) and with devices for the calculation of efficiency gains
| Training | Reference/device | Therapists required | Additional preparatory time |
|---|---|---|---|
| Walking in severely impaired patients | Reference | 2 | 10 |
| Lokomat | 0.5 | 15 | |
| Ekso/HAL | 1 | 15 | |
| Walking in moderately to mildly impaired patients | Reference | 1 | 5 |
| C-Mill/Treadmill/Andago | 1 | 5 | |
| FLOAT | 0.5 | 10 | |
| Lower extremity | Reference | 1 | 0 |
| Allegro | 0.5 | 10 | |
| Motomed LE | 0.3 | 10 | |
| Upper extremity | Reference | 1 | 5 |
| Armeo/Pablo | 0.5 | 10 | |
| Motomed UE | 0.5 | 10 | |
| Myro | 0.3 | 10 | |
| Hand | Reference | 1 | 5 |
| Gloreha, Yougrabber | 0.3 | 10 | |
| Whole body | Reference | 1 | 5 |
| Nustep | 0.3 | 5 | |
| Trunk | Reference | 1 | 5 |
| Valedo | 0.5 | 10 |
Fig. 1Screening and enrolment of study participants
Patients’ characteristics
| Characteristic |
|
|---|---|
|
| 60.8 ± 12.5 |
|
| |
| Female | 4 (28.6%) |
| Male | 10 (71.4%) |
|
| 26.2 ± 4.1 |
|
| |
| Ischemic stroke | 10 (71.4%) |
| Intracranial hemorrhage | 4 (28.6%) |
|
| |
| Left | 9 (64.3%) |
| Right | 5 (35.7%) |
|
| 24.9 ± 2.8 |
Number of devices with respective number of interventions
| Impairments addressed | Number of devices used | Number of interventions (total = 652) |
|---|---|---|
| Lower extremity and gait | 10 | 299 |
| Upper extremity | 9 | 201 |
| Other | 1 | 152 |
Comparison between scheduled and performed trainings
| Scheduled | |||||
|---|---|---|---|---|---|
| Performed | ≤ 15 min | 16–30 min | 31–45 min | > 45 min | Sum |
| 87 (22.8) | 5 (2.4) | 0 | 98 | ||
| 1 (12.5) | 58 (27.6) | 22 (47.8) | 322 | ||
| 0 | 31 (8.1) | 19 (41.3) | 182 | ||
| 0 | 1 (0.3) | 11 (5.2) | 17 | ||
| 0 | 22 (5.8) | 4 (1.9) | 0 | 26 | |
| 8 (100) | 382 (100) | 210 (100) | 46 (100) | 646 | |
In bold: trainings performed as scheduled, missing n = 6
Fig. 2Trainings with technological devices (n = 646) in minutes scheduled vs. actually performed
Fig. 3Perceived exertion during trainings
Patient-related outcomes pre- and post-intervention
| Pre-intervention | Post-intervention | Median change [95% CI] |
|
| |
|---|---|---|---|---|---|
|
| |||||
| 10MWT (in seconds) comfortable ( | 28.6 [22.9] | 19.0 [19.6] | − 1.75 [− 8.4 to − 0.6] | 0.014 | 0.738 [0.38–0.89] |
| 10MWT (in seconds) maximum ( | 21.6 [23.4] | 15.1 [19.3] | − 1.25 [− 9.5 to − 0.9] | 0.016 | 0.679 [0.29–0.89] |
| CSMA-WI, walking capacity | 16 [8.3] | 19 (7.8) | 2 [0.0–3.5] | NS | – |
| BBS, balance abilities | 32 [24] | 39 [18.8] | 5.5 [2.0–9.0] | 0.001 | 0.88 [0.88–0.89] |
| FAC, mobility status | 2 [2] | 3.5 (3) | 0.5 [0.0–1.0] | 0.015 | 0.703 [0.46–0.86] |
|
| |||||
| FMA-UE, upper extremity motor function | 16 [12.5] | 27.5 [23.8] | 8 [3.0–12.0] | 0.002 | 0.87 [0.84–0.91] |
| BBT, gross manual dexterity (affected side) | 0 [19.8] | 1 [30.8] | 1 [0.0–8.0] | 0.014 | 0.74 [0.53–0.86] |
|
| |||||
| SIS, stroke impact (64–320) | 219 [39.8] | 238 [38] | 13 [0.0–39.0] | 0.003 | 0.78 [0.54–0.88] |
| SIS, stroke recovery (0–100%) | 50 [35] | 65.5 [17.5] | 7.5 [− 5.0 to 30.0] | NS | – |
| FIM, generic functional performance | 102 [47.5] | 104.5 [32.5] | 5.0 [1.0–13.0] | 0.002 | 0.86 [0.78–0.89] |
| EQ-5D Index | 0.7 [0.16] | 0.8 [0.14] | 0.09 [0.0–0.1] | NS | – |
Sampling units: N = 14; CI confidence interval, P p-value provided by Wilcoxon signed-rank test, NS non-significant, r effect size r, calculated as z statistic extracted from a paired-sample Wilcoxon signed-rank test, divided by square root of the sample size, 10MWT 10 Meter Walking Test, CSMA-WI Chedoke-McMaster Stroke Assessment – Walking Index, BBS Berg Balance Scale, FAC Functional Ambulation Category, FMA-UE Fugl-Meyer Assessment -Upper Extremity, BBT Box&Block Test, SIS Stroke Impact Scale, FIM Functional Independence Measure
Fig. 4Efficiency gain in % staff time. The reference relates to the same trainings without devices